Gyre subsidiary receives China NMPA IND approval for F230 in pulmonary arterial hypertension

GYRE THERAPEUTICS, INC.

IND approved by CDE of China's NMPA for F230 tablets, a selective endothelin receptor antagonist for PAH.
F230 originally licensed from Eisai through Gyre's indirect stockholder GNI Group Ltd.
Preclinical data showed statistically significant reductions in mean pulmonary artery pressure and right ventricular systolic pressure.
CEO Han Ying stated commitment to advancing F230 through clinical development for PAH; other indications also being explored.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.